South Korea’s Ministry of Health and Welfare announced expanded national health-insurance coverage for three cancer-treatment groups from October 1, 2026. A named medicine in a press release is not an automatic approval for every person with the same broad diagnosis. Your oncology team must review the diagnosis, tests, treatment stage and current reimbursement criteria. This is not individual medical advice.

Separate the announcement from your eligibility

  • Retevmo capsules: the ministry described coverage for non-small-cell lung cancer with a RET fusion and medullary thyroid cancer with a RET mutation. A broad cancer diagnosis by itself does not establish the relevant genetic condition.
  • Vyloy injection: the announcement concerns unresectable advanced or metastatic gastric cancer, not all stages of stomach cancer.
  • Padcev plus Keytruda: the coverage expansion concerns a first-line combination for urothelial cancer. Do not assume that every standalone use or treatment line for either drug is covered.

Original information card distinguishing the therapy groups

The distinction between a RET fusion (lung cancer) and a RET mutation (medullary thyroid cancer) was cross-checked against an earlier HIRA reimbursement-assessment notice listing approved indications. That assessment is not the final patient-specific October reimbursement rule.

The ministry discusses possible clinical benefits. Population-level trial results and policy expectations do not predict or guarantee one patient's outcome. Nor does this announcement alone state every detailed reimbursement criterion for your situation.

Questions to bring to the consultation

  1. Does my exact diagnosis and test result fit the indication under discussion?
  2. Does my current treatment line make that medicine or combination regimen relevant?
  3. Which current coverage rule and out-of-pocket cost would apply to me, and how will the team verify them?

Original card for discussing diagnosis, line of therapy and coverage

Do not stop or change cancer treatment based on a blog post. Our shorter Korean Naver guide lists the first questions. The cover is AI-generated generic imagery, not a real product or patient; the information cards were produced separately.

About the Author

The Life Mokcha editorial team separates policy announcements from patient-specific clinical and insurance decisions.

References